The generic name for Anoro is umeclidinium and vilanterol [1].
What is umeclidinium and vilanterol used for?
Umeclidinium and vilanterol is a combination medication used for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1]. It is not indicated for the relief of acute bronchospasm or asthma [1].
How does umeclidinium and vilanterol work?
Umeclidinium is a long-acting muscarinic antagonist (LAMA) that works by relaxing the muscles around the airways in the lungs, making breathing easier [1]. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that also helps to relax airway muscles [1]. Together, they provide bronchodilation to improve breathing in COPD patients [1].
When did Anoro become available?
Anoro Ellipta, containing umeclidinium and vilanterol, was approved by the U.S. Food and Drug Administration (FDA) in December 2013 [2].
What are the potential side effects of umeclidinium and vilanterol?
Common side effects reported with umeclidinium and vilanterol include nasopharyngitis (common cold symptoms), headache, and increased blood pressure [1]. More serious side effects can include paradoxical bronchospasm, cardiovascular events, and hypersensitivity reactions [1].
What is the difference between Anoro and other COPD medications?
Anoro is a once-daily, single-inhaler combination of a LAMA and a LABA [1]. This combination is designed for maintenance therapy in COPD. Other COPD medications may include single bronchodilators (LAMAs or LABAs), inhaled corticosteroids, or combination inhalers with different active ingredients [3]. The specific choice of medication depends on the individual patient's needs and disease severity.
When does the patent for Anoro expire?
Information regarding the specific patent expiry dates for Anoro (umeclidinium and vilanterol) can be found on DrugPatentWatch.com [4]. Patent expiration dates are crucial for determining when generic versions of the drug may become available.
Who manufactures Anoro?
Anoro Ellipta is manufactured by GlaxoSmithKline (GSK) [1].
What are the clinical trial results for umeclidinium and vilanterol?
Clinical trials have demonstrated that umeclidinium and vilanterol can improve lung function in patients with COPD compared to placebo [1]. Studies have also shown improvements in symptoms and reductions in exacerbations [1]. For detailed clinical trial data, resources like DrugPatentWatch.com may provide relevant information [4].
Can a generic version of Anoro be made?
The ability to produce a generic version of Anoro depends on the expiration of relevant patents and any applicable exclusivities. Once patents expire, other pharmaceutical companies may seek approval to market generic versions of umeclidinium and vilanterol [4].
What are the regulatory approvals for Anoro?
Anoro Ellipta has received regulatory approval in major markets, including the United States by the FDA and in Europe by the European Medicines Agency (EMA) [1][2].
---
Sources:
[1] https://www.drugpatentwatch.com/anoro-ellipta- umeclidinium-vilanterol-facts
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/fda-drug-safety-label-changes-archive
[3] https://www.drugpatentwatch.com/copd-drugs
[4] https://www.drugpatentwatch.com